The present invention relates to a pharmaceutical dosage form comprising an active ingredient such as methotrexate or a pharmaceutically acceptable salt thereof, in particular in the form of pellets, such as multiparticulates, mini-tablets or granulate. It further relates to oral dosage forms for which saturation kinetics limits the oral use of higher dosages of active ingredients.

Customised polypills may be produced in the pharmacy from two or more drug packages using an assembly machine. Each drug package may comprise an array of cells containing individual doses of a single drug. The individual doses may be combined within the cells of the packages to produce an end user package with an array of cells containing the combined drugs in the form of individual polypills, which may be formed as capsules or pastilles. Label indicia of the drug packages may be combined together to form a composite label of the end user package. Serialization data may be read from the packages during assembly and sent to a remote server for authentication and supply chain management. In another aspect, patients who have a history of poor compliance with a prescribed oral antipsychotic while periodically seeking symptomatic relief from another prescribed psychoactive, are provided with both medicaments in the form of polypills to be taken in place of the solo antipsychotic when the patient is in crisis. Providing the preferred psychoactive as a combination motivates the patient to resume their antipsychotic therapy when symptoms return, which may result in better compliance and more effective management of psychosis in the community.

A miniature device configured to be maneuvered within a patient under manipulation by an external magnetic field and to selectively perform a predefined function is provided. The miniature device comprises a shell defining therewithin an internal cavity, and a magnetic arrangement disposed within the cavity. The miniature device is configured such that the magnetic arrangement, within a rotating magnetic field, effects one of performance of the function and propulsion of the miniature device within the patient, and, within a magnetic field gradient, effects the other of performance of the function and propulsion of the miniature device within the patient.

Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

The disclosure relates to compositions containing allyl isothiocyanate and methods of use thereof for stimulating tearing in a subject to treat dry eye.

Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral controlled release pharmaceutical compositions comprising fumarate esters suspended in liquid matrices are described. One embodiment described herein is a pharmaceutical composition comprising fumarate esters suspended in a lipid or lipophilic liquid with enhanced bioavailability.

Disclosed herein a pharmaceutical composition comprising aprepitant a pharmaceutically acceptable salt thereof; at least one hydrocarbon derivative selected from among a fatty acid of 14 to 18 carbon atoms, and a fatty alcohol of 14 to 18 carbon atoms; and at least one selected from among polyoxyethyelene-type nonionic surfactant, sucrose fatty acid ester, and Macrogol 15 hydroxystearate. The pharmaceutical composition of the present disclosure can release aprepitant or a pharmaceutically acceptable salt thereof to effectively exert the pharmaceutical efficacy, and can be dissolved in a fasted state simulated gastrointestinal fluid so that it can be useful for study on the in vivo pharmacokinetic behavior of aprepitant.

Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.

Controlled release preparations and soft capsules are provided. Also provided are emulsions and suspensions, including compositions and methods of manufacturing controlled release soft capsules, where the fill contains a suspension and/or an emulsion.

The present invention relates to extended release compositions of an amino-C2-C6-alkyl nitrate and of pharmaceutically acceptable salt thereof, in particular 2-aminoethyl nitrate, and to fixed dose combinations with further pharmaceutically active drug substances. 2-Aminoethyl nitrate does not provoke nitrate tolerance, but has a very short half life in physiological systems.